These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 24883145)

  • 1. Pharmacokinetic changes and dosing modification of aminoglycosides in critically ill obese patients: a literature review.
    Velissaris D; Karamouzos V; Marangos M; Pierrakos C; Karanikolas M
    J Clin Med Res; 2014 Aug; 6(4):227-33. PubMed ID: 24883145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aminoglycoside Dosing and Volume of Distribution in Critically Ill Surgery Patients.
    Grucz TM; Kruer RM; Bernice F; Lipsett PA; Dorman T; Sugrue D; Jarrell AS
    Surg Infect (Larchmt); 2020 Dec; 21(10):859-864. PubMed ID: 32302517
    [No Abstract]   [Full Text] [Related]  

  • 3. Aminoglycosides in the Intensive Care Unit: What Is New in Population PK Modeling?
    Duong A; Simard C; Wang YL; Williamson D; Marsot A
    Antibiotics (Basel); 2021 Apr; 10(5):. PubMed ID: 33946905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of extended-interval aminoglycoside dosing strategies for the treatment of moderate-to-severe infections encountered in critically ill surgical patients.
    Mueller EW; Boucher BA
    Surg Infect (Larchmt); 2009 Dec; 10(6):563-70. PubMed ID: 20035611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aminoglycosides against carbapenem-resistant Enterobacteriaceae in the critically ill: the pitfalls of aminoglycoside susceptibility.
    Zavascki AP; Klee BO; Bulitta JB
    Expert Rev Anti Infect Ther; 2017 Jun; 15(6):519-526. PubMed ID: 28375030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Experience with a once-daily dosing program of aminoglycosides in critically ill patients.
    Buijk SE; Mouton JW; Gyssens IC; Verbrugh HA; Bruining HA
    Intensive Care Med; 2002 Jul; 28(7):936-42. PubMed ID: 12122533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive Guidance for Antibiotic Dosing in Obese Adults.
    Meng L; Mui E; Holubar MK; Deresinski SC
    Pharmacotherapy; 2017 Nov; 37(11):1415-1431. PubMed ID: 28869666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aminoglycosides in critically ill patients: which dosing regimens for which pathogens?
    Marsot A; Hraiech S; Cassir N; Daviet F; Parzy G; Blin O; Papazian L; Guilhaumou R
    Int J Antimicrob Agents; 2020 Oct; 56(4):106124. PubMed ID: 32739478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aminoglycoside dosing considerations in intensive care unit patients.
    Watling SM; Dasta JF
    Ann Pharmacother; 1993 Mar; 27(3):351-7. PubMed ID: 8267695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetics of aminoglycosides in critically ill trauma patients on once-daily regimens.
    Barletta JF; Johnson SB; Nix DE; Nix LC; Erstad BL
    J Trauma; 2000 Nov; 49(5):869-72. PubMed ID: 11086778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and Target Attainment of Antibiotics in Critically Ill Children: A Systematic Review of Current Literature.
    Hartman SJF; Brüggemann RJ; Orriëns L; Dia N; Schreuder MF; de Wildt SN
    Clin Pharmacokinet; 2020 Feb; 59(2):173-205. PubMed ID: 31432468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Altered aminoglycoside pharmacokinetics in critically ill patients with sepsis.
    Mann HJ; Fuhs DW; Awang R; Ndemo FA; Cerra FB
    Clin Pharm; 1987 Feb; 6(2):148-53. PubMed ID: 3665367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Variable pharmacokinetics of extended interval tobramycin or gentamicin among critically ill patients undergoing continuous venovenous hemofiltration.
    Chuk AC; Saeed F; Kousar N; Burrill S; Barns B; Rickrode G; Fu J; Katrych O; Saunders-Hao P; Block C; Lahey T
    Clin Nephrol; 2015 Oct; 84(4):214-21. PubMed ID: 26308080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of weight on aminoglycoside pharmacokinetics in normal weight and morbidly obese patients.
    Bauer LA; Edwards WA; Dellinger EP; Simonowitz DA
    Eur J Clin Pharmacol; 1983; 24(5):643-7. PubMed ID: 6873144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amikacin in Critically Ill Patients: A Review of Population Pharmacokinetic Studies.
    Marsot A; Guilhaumou R; Riff C; Blin O
    Clin Pharmacokinet; 2017 Feb; 56(2):127-138. PubMed ID: 27324191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aminoglycosides' dosing and monitoring practices in critically ill patients in Quebec hospitals.
    Duong A; Thirion DJG; Williamson D; Simard C; Marsot A
    J Chemother; 2022 Sep; 34(5):341-344. PubMed ID: 35238282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of Antimicrobials in Obese Children.
    Sampson M; Cohen-Wolkowiez M; Benjamin D; Capparelli E; Watt K
    GaBI J; 2013; 2(2):76-81. PubMed ID: 25009734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploring the Relationship between FEV
    Hoff BM; Scheetz MH; Jain M; Cullina JF; Rhodes NJ
    Pharmacotherapy; 2020 Jun; 40(6):584-591. PubMed ID: 32259317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simplified estimation of aminoglycoside pharmacokinetics in underweight and obese adult patients.
    Pai MP; Nafziger AN; Bertino JS
    Antimicrob Agents Chemother; 2011 Sep; 55(9):4006-11. PubMed ID: 21670189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An Evaluation of Gentamicin, Tobramycin, and Amikacin Pharmacokinetic/Pharmacodynamic Parameters in HIV-Infected Children.
    Rodriguez JC; Schoenike S; Scott GB; Rossique-Gonzalez MT; Gomez-Marin O
    J Pediatr Pharmacol Ther; 2003 Oct; 8(4):274-83. PubMed ID: 23118683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.